XOMA (XOMA) News Today $23.88 -0.66 (-2.69%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Acuitas Investments LLC Has $1.60 Million Position in XOMA Co. (NASDAQ:XOMA)Acuitas Investments LLC lowered its stake in shares of XOMA Co. (NASDAQ:XOMA - Free Report) by 31.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,704 shares of the biotechnology company's stock after selling 27,354 sFebruary 18 at 5:33 AM | marketbeat.comXOMA (NASDAQ:XOMA) Upgraded by StockNews.com to Hold RatingStockNews.com upgraded shares of XOMA from a "sell" rating to a "hold" rating in a report on Tuesday.February 11, 2025 | marketbeat.comXOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comXOMA (NASDAQ:XOMA) Downgraded to Sell Rating by StockNews.comStockNews.com cut XOMA from a "hold" rating to a "sell" rating in a report on Monday.February 3, 2025 | marketbeat.comXOMA (NASDAQ:XOMA) Price Target Lowered to $104.00 at HC WainwrightHC Wainwright lowered their price target on XOMA from $123.00 to $104.00 and set a "buy" rating on the stock in a report on Monday.February 3, 2025 | marketbeat.comInsider Selling: XOMA Co. (NASDAQ:XOMA) Major Shareholder Sells 500,742 Shares of StockXOMA Co. (NASDAQ:XOMA - Get Free Report) major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.January 28, 2025 | marketbeat.comXOMA (NASDAQ:XOMA) Stock Rating Upgraded by StockNews.comStockNews.com raised XOMA from a "sell" rating to a "hold" rating in a research report on Thursday.January 16, 2025 | marketbeat.comOptimistic Long-term Revenue Potential for Xoma Driven by Vabysmo Royalties and Market PerformanceJanuary 15, 2025 | markets.businessinsider.comXOMA Royalty Corporation: High-Risk Royalty Aggregator Best AvoidedJanuary 15, 2025 | seekingalpha.comBuy Rating for Xoma Driven by Promising Drug Advancements and Strong Partnership PipelineJanuary 8, 2025 | markets.businessinsider.comStockNews.com Downgrades XOMA (NASDAQ:XOMA) to SellStockNews.com lowered XOMA from a "hold" rating to a "sell" rating in a research note on Wednesday.January 8, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for XOMA (NASDAQ:XOMA)HC Wainwright reiterated a "buy" rating and set a $123.00 target price on shares of XOMA in a research report on Tuesday.January 7, 2025 | marketbeat.comXOMA Corp - 8.375% DP PFD B goes ex dividend tomorrowJanuary 2, 2025 | msn.comXOMA Co. (NASDAQ:XOMA) Sees Significant Growth in Short InterestXOMA Co. (NASDAQ:XOMA - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 139,000 shares, a growth of 23.4% from the November 30th total of 112,600 shares. Based on an average daily volume of 29,100 shares, the short-interest ratio is presently 4.8 days.December 29, 2024 | marketbeat.comXOMA (NASDAQ:XOMA) Lowered to "Sell" Rating by StockNews.comStockNews.com downgraded XOMA from a "hold" rating to a "sell" rating in a research note on Friday.December 27, 2024 | marketbeat.comXOMA Corp - 8.375% DP PFD B declares $0.5234 dividendDecember 19, 2024 | seekingalpha.comXOMA Preferred Shares Series A declares $0.5391 dividendDecember 19, 2024 | seekingalpha.comXOMA Royalty Declares Quarterly Preferred Stock DividendsDecember 19, 2024 | globenewswire.comXoma’s Strategic Partnerships and Promising Pipeline Drive Buy RatingDecember 14, 2024 | markets.businessinsider.comXOMA's (XOMA) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $123.00 target price on shares of XOMA in a report on Friday.December 13, 2024 | marketbeat.comXOMA Co. (NASDAQ:XOMA) Shares Sold by Fmr LLCFmr LLC decreased its position in shares of XOMA Co. (NASDAQ:XOMA - Free Report) by 4.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,102,401 shares of the biotechnology company's stocDecember 10, 2024 | marketbeat.comA Glimpse Into The Expert Outlook On XOMA Royalty Through 4 AnalystsDecember 3, 2024 | benzinga.comStrategic Acquisitions and Growth Potential Bolster Xoma’s Buy RatingDecember 3, 2024 | markets.businessinsider.comXOMA Royalty Owns Economic Interest In Seralutinib With Pulmokine Purchase; Stock UpDecember 2, 2024 | markets.businessinsider.comXOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its PortfolioDecember 2, 2024 | finance.yahoo.comXOMA (XOMA) Stock Surges Amid Positive Market MovementNovember 26, 2024 | gurufocus.comTop Wall Street Forecasters Revamp Twist Bioscience Price Expectations Ahead Of Q4 EarningsNovember 18, 2024 | benzinga.comXOMA Co. (NASDAQ:XOMA) Sees Significant Decrease in Short InterestXOMA Co. (NASDAQ:XOMA - Get Free Report) was the recipient of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 173,300 shares, a drop of 23.5% from the October 15th total of 226,400 shares. Based on an average trading volume of 22,100 shares, the days-to-cover ratio is presently 7.8 days.November 15, 2024 | marketbeat.comOwen Hughes Sells 21,881 Shares of XOMA Co. (NASDAQ:XOMA) StockNovember 14, 2024 | insidertrades.comWhat is HC Wainwright's Estimate for XOMA FY2025 Earnings?XOMA Co. (NASDAQ:XOMA - Free Report) - Investment analysts at HC Wainwright raised their FY2025 earnings estimates for XOMA in a note issued to investors on Thursday, November 7th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of $0.17 per sharNovember 11, 2024 | marketbeat.comXOMA Royalty Corporation (NASDAQ:XOMA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their EstimatesNovember 10, 2024 | finance.yahoo.comXOMA Royalty Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsNovember 9, 2024 | finance.yahoo.comXOMA Royalty’s Third Quarter 2024 Financial InsightsNovember 8, 2024 | markets.businessinsider.comStrategic Positioning and Growth Potential Drive Buy Rating for XomaNovember 8, 2024 | markets.businessinsider.comXOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent ActivitiesNovember 7, 2024 | globenewswire.comXOMA (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average - Here's WhyXOMA (NASDAQ:XOMA) Stock Crosses Above Two Hundred Day Moving Average - Here's WhyNovember 5, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for XOMA (NASDAQ:XOMA)HC Wainwright restated a "buy" rating and issued a $117.00 price target on shares of XOMA in a research report on Wednesday.October 23, 2024 | marketbeat.comXoma enters $15M royalty monetization arrangement with Twist BioscienceOctober 22, 2024 | markets.businessinsider.comXoma’s Strategic Partnerships and Pipeline Growth Position It as a Strong Investment OpportunityOctober 22, 2024 | markets.businessinsider.comXOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist BioscienceOctober 22, 2024 | globenewswire.comEllsworth Advisors LLC Makes New $516,000 Investment in XOMA Co. (NASDAQ:XOMA)Ellsworth Advisors LLC acquired a new stake in shares of XOMA Co. (NASDAQ:XOMA - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 19,475 shares of the biotechnology company's stock, valuedOctober 19, 2024 | marketbeat.comXOMA Stock Dips Amidst Biotech Sector DeclineOctober 3, 2024 | gurufocus.comXOMA (NASDAQ:XOMA) Shares Pass Above 200-Day Moving Average of $25.91XOMA (NASDAQ:XOMA) Shares Pass Above 200-Day Moving Average of $25.91September 28, 2024 | marketbeat.comXOMA Poised for Growth: FDA Approval of Miplyffa and Strategic Acquisitions Underpin Buy RatingSeptember 25, 2024 | markets.businessinsider.comZevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)September 23, 2024 | globenewswire.comXOMA Royalty Declares Quarterly Preferred Stock DividendsSeptember 23, 2024 | globenewswire.comXOMA (NASDAQ:XOMA) Stock Passes Above 200 Day Moving Average of $25.74XOMA (NASDAQ:XOMA) Stock Price Passes Above 200-Day Moving Average of $25.74September 17, 2024 | marketbeat.comXOMA Royalty Corp. 8.625% Pfd. Series ASeptember 5, 2024 | wsj.comXOMA Royalty to Present at Upcoming Investor Conferences in SeptemberSeptember 4, 2024 | globenewswire.comXOMA (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average of $25.53XOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving Average of $25.53September 4, 2024 | marketbeat.com Get XOMA News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address XOMA Media Mentions By Week XOMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XOMA News Sentiment▼1.630.60▲Average Medical News Sentiment XOMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XOMA Articles This Week▼11▲XOMA Articles Average Week Get XOMA News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Innoviva News OPKO Health News Emergent BioSolutions News Rigel Pharmaceuticals News Codexis News Ironwood Pharmaceuticals News Verastem News Vanda Pharmaceuticals News Sangamo Therapeutics News Lexicon Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XOMA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.